Skip to main content
Erschienen in: The Journal of Obstetrics and Gynecology of India 1/2016

19.11.2015 | Original Article

A Prospective Study of Placental Growth Factor Assay as a Novel Biomarker in Predicting Early-Onset Preeclampsia in High-Risk Patients

verfasst von: Pooja Mathur, Poonam Mathur, Laxmi Maru, Anupama Dave

Erschienen in: The Journal of Obstetrics and Gynecology of India | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Preeclampsia is a leading cause of maternal and perinatal mortality and morbidity, but signs and symptoms are non-specific and may vary. The root cause is imbalance of circulating angiogenic factors of placental (syncytiotrophoblast) origin, with consequent low levels of placental growth factor (PlGF) which may aid in diagnosis and prediction of disease.

Aims and Objectives

To study the incidence of women at risk of developing early-onset preeclampsia by plasma placental growth factor biomarker assay in high-risk patients, to assess the maternal outcome in patients with PlGF values below cutoff for presenting gestational age, to calculate sensitivity, specificity, positive predictive value and negative predictive value of PlGF assay in predicting preeclampsia and to conclude whether PlGF biomarker assay can be an effective screening test in high-risk patients for prediction of early-onset preeclampsia.

Materials and Methods

The study was carried out in the Department of Obstetrics and Gynecology at a tertiary care center. It is a prospective study, and study period extended from April 2012 to October 2013. One hundred pregnant women with 20- to 34-week gestational age with possible high risk of developing preeclampsia attending the antenatal clinics and high-risk OPDs were screened in the present study after explaining the nature of the study. PLGF concentration was quantitated using plasma and processed in Triage kit device (fluorescence immunoassay device). PLGF concentration was categorized against a specific range for specific gestation, and values below the range or <12 pg/ml were considered screened positives. The cases were followed up till delivery.

Results

Twenty-two cases were screened positive, of which 20 developed preeclampsia with a strong positive prediction value of more than 90 %.

Conclusion

PLGF is a strong predictor and a useful assay for early-onset preeclampsia.
Literatur
1.
Zurück zum Zitat Menzies J, Magee LA, Macnab YC, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy. 2007;26:447–62.CrossRefPubMed Menzies J, Magee LA, Macnab YC, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy. 2007;26:447–62.CrossRefPubMed
2.
Zurück zum Zitat Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981–91.CrossRefPubMed Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981–91.CrossRefPubMed
3.
Zurück zum Zitat Magee LA, von Dadelszen P, Chan S, et al. The control of hypertension in pregnancy study pilot trial. BJOG. 2007;114:770.e13–20.CrossRef Magee LA, von Dadelszen P, Chan S, et al. The control of hypertension in pregnancy study pilot trial. BJOG. 2007;114:770.e13–20.CrossRef
5.
Zurück zum Zitat Maynard S, Min J, Merchan J, et al. Excess placental soluble FMS-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.CrossRefPubMedPubMedCentral Maynard S, Min J, Merchan J, et al. Excess placental soluble FMS-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Venkatesha A, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.CrossRefPubMed Venkatesha A, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–9.CrossRefPubMed
7.
Zurück zum Zitat Levine R, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.CrossRefPubMed Levine R, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992–1005.CrossRefPubMed
8.
Zurück zum Zitat Taylor R, Grimwood J, Taylor R, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188:177–82.CrossRefPubMed Taylor R, Grimwood J, Taylor R, et al. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003;188:177–82.CrossRefPubMed
9.
Zurück zum Zitat Buhimschi C, Norwitz E, Funai E, et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005;192:734–41.CrossRefPubMed Buhimschi C, Norwitz E, Funai E, et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol. 2005;192:734–41.CrossRefPubMed
10.
Zurück zum Zitat Levine R, Maynard S, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–82.CrossRefPubMed Levine R, Maynard S, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–82.CrossRefPubMed
11.
Zurück zum Zitat Wikstrom A, Larsson A, Eriksson U, et al. Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007;109:1368–74.CrossRefPubMed Wikstrom A, Larsson A, Eriksson U, et al. Placental growth factor and soluble fms-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007;109:1368–74.CrossRefPubMed
12.
Zurück zum Zitat Romero R, Nien J, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational neonate. J Matern Fetal Neonatal Med. 2008;21:9–23.CrossRefPubMedPubMedCentral Romero R, Nien J, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational neonate. J Matern Fetal Neonatal Med. 2008;21:9–23.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ohkuchi A, Hirashima C, Matsubara S, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151–9.CrossRefPubMed Ohkuchi A, Hirashima C, Matsubara S, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151–9.CrossRefPubMed
14.
Zurück zum Zitat Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205:469.e1–8.CrossRef Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205:469.e1–8.CrossRef
15.
Zurück zum Zitat Sharon Maynard Annu. Rev. Med. 2008.59:61–78. Downloaded from arjournals.annualreviews.org by Mr Paul Sheard on 03/19/08. Sharon Maynard Annu. Rev. Med. 2008.59:61–78. Downloaded from arjournals.annualreviews.org by Mr Paul Sheard on 03/19/08.
16.
Zurück zum Zitat Triage® PLGF Test Product Insert.2011. Triage® PLGF Test Product Insert.2011.
17.
Zurück zum Zitat Sibai BM. Hypertension. In: Gabbe SG, Niebyl JR, Galen H, et al., editors. Obstetrics: Normal and problem pregnancies. 6th ed. New York: Elsevier; 2012. p. 779–822.CrossRef Sibai BM. Hypertension. In: Gabbe SG, Niebyl JR, Galen H, et al., editors. Obstetrics: Normal and problem pregnancies. 6th ed. New York: Elsevier; 2012. p. 779–822.CrossRef
18.
Zurück zum Zitat Hirashima C, Ohkuchi A, Arai F, et al. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res. 2005;28:727–32.CrossRefPubMed Hirashima C, Ohkuchi A, Arai F, et al. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res. 2005;28:727–32.CrossRefPubMed
19.
Zurück zum Zitat Cnossen JS, ter Riet G, Mol BW, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand. 2009;88:758–65.CrossRefPubMed Cnossen JS, ter Riet G, Mol BW, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand. 2009;88:758–65.CrossRefPubMed
20.
Zurück zum Zitat Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2009;201:e1–11. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2009;201:e1–11.
21.
Zurück zum Zitat Knudsen UB, Kronbog CS, von Dadelszen P, et al. Pregnancy hypertension: an international Journal of Women’s Cardiovascular. Health. 2012;2:8–15.CrossRef Knudsen UB, Kronbog CS, von Dadelszen P, et al. Pregnancy hypertension: an international Journal of Women’s Cardiovascular. Health. 2012;2:8–15.CrossRef
Metadaten
Titel
A Prospective Study of Placental Growth Factor Assay as a Novel Biomarker in Predicting Early-Onset Preeclampsia in High-Risk Patients
verfasst von
Pooja Mathur
Poonam Mathur
Laxmi Maru
Anupama Dave
Publikationsdatum
19.11.2015
Verlag
Springer India
Erschienen in
The Journal of Obstetrics and Gynecology of India / Ausgabe Sonderheft 1/2016
Print ISSN: 0971-9202
Elektronische ISSN: 0975-6434
DOI
https://doi.org/10.1007/s13224-015-0793-7

Weitere Artikel der Sonderheft 1/2016

The Journal of Obstetrics and Gynecology of India 1/2016 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.